OBJECTIVE:To investigate the clinical efficacy of budesonide combined with terbutaline in compressing atomized inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD). METHODS:116 cases with AECOPD from Jul. 2012 to Dec. 2014 were divided into observation group and control group according to random number table, with 58 cases in each group. The control group received conventional treatment of internal medicine, and based on the control group, the observation group additionally received budesonide combined with terbutaline in compressing atomized inhalation. The therapeutic efficacy, blood gas analysis index, pulmonary function and dyspnea score before and after treatment between two groups were compared. RESULTS: The effective rate of observation treatment group was 94. 83%, which was significantly higher than that of the control group 81. 03%, the difference was statistically significant (P<0. 05). FEV1, FEV1/predicated value, FEV1/FVC, PAO2, PACO2 and dyspnea score in the observation group after treatment improved more obviously than before treatment, and compared with the control group after treatment, the observation group improved the indexes more obvious, the difference was statistically significant ( P < 0. 05 ). CONCLUSIONS:Budesonide combined with terbutaline in compressing atomized inhalation in treatment of AECOPD can significantly improve symptoms of dyspnea, relieve the symptoms of hypoxia, improve pulmonary function, with a satisfactory clinical efficacy. It is worthy of clinical application.%目的:探讨布地奈德联合特布他林压缩雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床疗效. 方法:选择2012 年7月-2014年12月收治的慢性阻塞性肺病急性加重期患者116例,按随机数字表法分为观察组和对照组各58例,对照组患者采用内科常规治疗方法,观察组患者在对照组基础上采用布地奈德联合特布他林雾化吸入治疗. 比较2组患者的治疗效果、血气分析指标、肺功能及呼吸困难评分情况. 结果:观察组患者治疗有效率为94. 83%,明显高于对照组的81. 03%,差异有统计学意义(P<0. 05);与治疗前比较,观察组患者治疗后第一秒用力呼气量、第一秒用力呼气量/预计值、第一秒用力呼气量/用力肺活量、动脉氧分压和动脉血二氧化碳分压以及呼吸困难评分明显改善,差异有统计学意义( P<0. 05 );与对照组治疗后比较,观察组患者各指标改善程度明显,差异有统计学意义(P<0. 05). 结论:布地奈德联合特布他林压缩雾化吸入可明显改善慢性阻塞性肺病急性加重期患者呼吸困难、缺氧等症状,改善肺功能,疗效较好,值得临床推广.
展开▼
